Targets › DRD2
64 programs from 52 companies in 119 trials: 41 Phase 3, 35 Phase 2, 32 Phase 4, 11 Phase 1; Psychiatry, Neurology, Other; next expected readout Nov 2026.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P14416)
Open in Phaseline: the race on DRD2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals | iloperidone Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR2A | Phase 4 | Schizophrenia; Hypertension | Nov 2026 |
| Sanliurfa Education and Research Hospital | metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 4 | Intraoperative Nausea-retching-vomiting Episodes | Jan 2027 |
| The University of Texas Health Science Center at San Antonio | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Parkinson's Disease Psychosis | Feb 2027 |
| New York State Psychiatric Institute | Olanzapine-samidorphan Atypical antipsychotic (D2 dopamine receptor antagonist) combined with opioid antagonist ( | DRD2, OPRK1 | Phase 4 | Schizophenia Disorder | Apr 2027 |
| University of Texas Southwestern Medical Center | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Apr 2027 |
| The Chaim Sheba Medical Center | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Centre Hospitalier Universitaire, Amiens | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Clozapine | Sep 2027 |
| Centre for Addiction and Mental Health | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Sep 2027 |
| Centre for Addiction and Mental Health | Paliperidone Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR2A | Phase 4 | Schizophrenia and Related Disorders | Sep 2027 |
| Centre for Addiction and Mental Health | Risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Schizophrenia and Related Disorders | Sep 2027 |
| Dennis M. McNamara, MD, MS | Bromocriptine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Peripartum Cardiomyopathy, Postpartum | Jun 2028 |
| New York State Psychiatric Institute | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Jun 2028 |
| Dr. Inge Winter | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia and Related Disorders | Jun 2028 |
| Northwell Health | aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Northwell Health | risperidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Psychosis; Acute; Schizophenia Disorder | Dec 2029 |
| Jimmi Nielsen | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophrenia | Dec 2029 |
| Massachusetts General Hospital | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 4 | Bipolar I Disorder | Feb 2030 |
| Massachusetts General Hospital | Lurasidone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Bipolar I Disorder | Feb 2030 |
| Massachusetts General Hospital | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 4 | Bipolar I Disorder | Feb 2030 |
| Northwell Health | clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 4 | Schizophenia Disorder | Jul 2030 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Flupentixol-Melitracen Antipsychotic-antidepressant combination; flupentixol is a dopamine antagonist, melitracen | DRD2, SLC6A3 | Phase 4 | Thyroid-Associated Ophthalmopathy | – |
| Massachusetts General Hospital | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 4 | Adrenoleukodystrophy | – |
| Changchun GeneScience Pharmaceutical | Cabergoline Dopamine D2 receptor agonist | DRD2 | Phase 3 | Hyperprolactinemia; Prolactinoma; Pituitary Neoplasms; Gynecologic Disease … | Nov 2026 |
| Jimma University | Bromocriptine mesylate D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Dilated Cardiomyopathy | Nov 2026 |
| Gedeon Richter | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Schizophrenia; Depression, Bipolar; Bipolar I Disorder | Dec 2026 |
| AbbVie | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 3 | Depression | Mar 2027 |
| Intra-Cellular Therapies | Lumateperone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor | HTR2A, DRD2, SLC6A4 | Phase 3 | Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia … | Apr 2027 |
| LB Pharmaceuticals | LB-102 Atypical antipsychotic; dopamine D2/D3 receptor antagonist | DRD2, DRD3 | Phase 3 | Schizophrenia; Bipolar I Disorder | Jun 2027 |
| Shanghai Mental Health Center | Aripiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Treatment-resistant Schizophrenia; Obsessive-Compulsive Disorder | Jun 2027 |
| Otsuka | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 3 | Acute Schizophrenia | Sep 2027 |
| M.D. Anderson Cancer Center | Domperidone Dopamine D2 receptor antagonist | DRD2 | Phase 3 | Digestive System Disorder | Oct 2027 |
| Affiliated Hospital of Qinghai University | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 3 | Nausea | Dec 2027 |
| Prilenia | Pridopidine Dopamine D2 receptor modulator | DRD2 | Phase 3 | Amyotrophic Lateral Sclerosis; Huntington Disease | Mar 2028 |
| Foundation for Advancing Veterans' Health Research | Quetiapine Fumarate Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 3 | Mild Traumatic Brain Injury | Jun 2028 |
| Gustave Roussy, Cancer Campus, Grand Paris | ONC201 DRD2 antagonist; also exhibits TRAIL pathway activation | DRD2 | Phase 3 | Diffuse Intrinsic Pontine Glioma | Sep 2028 |
| Daniel Lindqvist | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Bipolar Disorder (BD) | Dec 2029 |
| Shanghai Mental Health Center | Amisulpride Atypical antipsychotic; selective dopamine D2 and D3 receptor antagonist | DRD2, DRD3 | Phase 3 | Treatment-resistant Schizophrenia | Dec 2030 |
| Shanghai Mental Health Center | Clozapine Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, DRD2 | Phase 3 | Treatment-resistant Schizophrenia | Dec 2030 |
| MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals | Apomorphine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Idiopathic Parkinson's Disease | – |
| Reviva Pharmaceuticals | Brilaroxazine (RP5063) Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist | DRD2, HT1A | Phase 3 | Schizophrenia | – |
| I.R.C.C.S. Fondazione Santa Lucia | Rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 3 | Alzheimer Disease | – |
| University of California, San Diego | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Anxiety Disorders | Nov 2026 |
| Carmen Clapp | levosulpiride dopamine D2 receptor antagonist | DRD2 | Phase 2 | Diabetic Macular Edema | Dec 2026 |
| University of Liege | Apomorphine Hydrochloride D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Disorder of Consciousness | Dec 2026 |
| M.D. Anderson Cancer Center | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium | Feb 2027 |
| M.D. Anderson Cancer Center | Haloperidol Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor inverse agonist | HTR2A, DRD2, DRD3, DRD4 | Phase 2 | Delirium; Advanced Malignant Neoplasm; Advanced Cancers | Feb 2027 |
| Instituto do Cancer do Estado de São Paulo | Amisulpride Dopamine D2 and D3 receptor antagonist | DRD2, DRD3 | Phase 2 | Post Operative Nausea and Vomiting (PONV) | Mar 2027 |
| Jazz Pharmaceuticals | JZP3507 (ONC206) DRD2 agonist | DRD2 | Phase 2 | Meningioma; Advanced Pheochromocytoma and Paraganglioma; Central Nervous System Neoplasms | Mar 2027 |
| Boryung Pharmaceutical | Olanzapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy … | May 2027 |
| Simon Fisher | Metoclopramide Dopamine D2 receptor antagonist; Serotonin 3a (5-HT3a) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist | DRD2, HTR3A, HTR4 | Phase 2 | Hypoglycemia Unawareness | Jun 2027 |
| Clinical Academic Center (2CA-Braga) | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Obsessive-Compulsive Disorder | Aug 2028 |
| Lone Baandrup | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 2 | Psychiatric Disorders | Feb 2029 |
| Göteborg University | OSU6162 Dopamine D2 receptor antagonist (putative) | DRD2 | Phase 2 | Depression; Bipolar Depression | May 2029 |
| University Hospital, Rouen | rotigotine D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Kidney Diseases | Jul 2030 |
| Stanford University | Pramipexole D2-like dopamine receptor agonist | DRD2, DRD3, DRD4 | Phase 2 | Depression - Major Depressive Disorder | Aug 2030 |
| Md. Moktadirul Hoque Shuvo | Trifluoperazine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, HTR2C, DRD2, DRD3, DRD4 | Phase 2 | Functional Dyspepsia | – |
| Mapi Pharma | Cariprazine Dopamine D3 receptor modulator; Dopamine D2 receptor modulator | DRD3, DRD2 | Phase 1 | Schizophrenia | Dec 2026 |
| Serina Therapeutics | SER-252 (PEOZ-apomorphine) Dopamine receptor agonist (D1-like and D2-like dopamine receptors) | DRD1, DRD2, DRD3, DRD4, DRD5 | Phase 1 | PARKINSON DISEASE (Disorder) | Jan 2027 |
| University of Arizona | Ziprasidone Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Schizophrenia | Feb 2027 |
| Sabine Mueller, MD, PhD | ONC206 DRD2 antagonist / ClpP agonist | DRD2, CLPP | Phase 1 | Diffuse Midline Glioma (DMG) | May 2027 |
| Anxo Pharmaceutical | AX251 LAI Dopamine D2/D3 receptor partial agonist | DRD2, DRD3 | Phase 1 | Schizophrenia | Jul 2028 |
| Sichuan Kelun Pharmaceutical | Brexpiprazole Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR1A, HTR2A | Phase 1 | Schizophrenia Disorders; Major Depressive Disorder; Bipolar Depression; Alcohol Use Disorder | – |
| Capital Medical University | Chlorpromazine Serotonin 2a (5-HT2a) receptor antagonist; D2-like dopamine receptor antagonist | HTR2A, DRD2, DRD3, DRD4 | Phase 1 | Acute Ischemic Stroke | – |
| Verinder Sharma | Quetiapine Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Dopamine D2 receptor antagonist | HTR2A, HTR2C, DRD2 | Phase 1 | Postpartum Depression | – |
Schizophrenia (17) Bipolar I Disorder (5) Schizophenia Disorder (4) Schizophrenia and Related Disorders (4) Bipolar Depression (3) Delirium (3) Treatment-resistant Schizophrenia (3) Amyotrophic Lateral Sclerosis (2) Hyperprolactinemia (2) Prolactinoma (2) Migraine (2) Major Depressive Disorder (2)
small molecule (56), protein or peptide (6), mixed (1), antibody (1)
Massachusetts General Hospital (4) Centre for Addiction and Mental Health (3) M.D. Anderson Cancer Center (3) Northwell Health (3) Shanghai Mental Health Center (3) New York State Psychiatric Institute (2) Prilenia (1) Changchun GeneScience Pharmaceutical (1) Vanda Pharmaceuticals (1) Intra-Cellular Therapies (1) The Chaim Sheba Medical Center (1) Verinder Sharma (1) LB Pharmaceuticals (1) Sichuan Kelun Pharmaceutical (1) Gedeon Richter (1) Jazz Pharmaceuticals (1) Serina Therapeutics (1) Göteborg University (1) Boryung Pharmaceutical (1) University of Arizona (1)
HTR2A (31) DRD3 (24) DRD4 (17) HTR2C (11) HTR1A (5) HTR3A (3) HTR4 (3) SLC6A4 (1) OPRK1 (1) DRD1 (1) DRD5 (1) CLPP (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.